FDA official overseeing food policy and response to resign in wake of baby formula shortage

FDA official overseeing food policy and response to resign in wake of baby formula shortage


A sign for the Food and Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.

Sarah Silbiger | Getty Images

Frank Yiannas, a top official at the Food and Drug Administration in charge of the agency’s food policy and response office, announced Wednesday that he is stepping down from his role as deputy commissioner.

Yiannas was among the FDA officials leading the agency as it navigated its way through last year’s infant formula shortage after Abbott Laboratories voluntarily shut down production at the country’s largest formula factory following reports that infants who consumed formula from the plant got sick.

His resignation comes days after Abbott Laboratories confirmed that the Justice Department was investigating the company over its Michigan baby formula plant.

“Today, I informed Commissioner [Robert] Califf that I will be resigning my position as Deputy Commissioner for the Office of Food Policy and Response effective February 24 ,” Yiannas tweeted. “I am honored to have served the American public, alongside each and every one of you, over these past four years.”

Since December of 2018, Yiannas has been involved in the development and rollout of policies related to food safety, including response to outbreaks, tracing foodborne illness investigations, product recalls and supply chain innovation.

Yiannas’ resignation announcement comes weeks after an expert panel issued a scathing report on its investigation of the FDA’s processes and organizational structure for its foods program. The panel criticized, among other things, a “culture, structure, and governance model” that detracts from the program’s effectiveness.

That investigation, was ordered by FDA Commissioner Robert Califf in July, following growing criticism that the agency had mishandled the formula crisis after illnesses were reported.

Yiannas’ resignation letter, obtained by the Washington Post, referenced inheriting a “decentralized structure” at the agency’s foods program he operated, which he said “significantly impaired FDA’s ability to operate as an integrated food team and protect the public.”

NBC News has reached out to Yiannas for comment.

In a statement, the FDA lauded Yiannas for his service on the agency’s leadership team, saying his efforts to tackle key initiatives helped “create a safer and more digital, traceable food system for our country.”

“The FDA remains committed to providing an update on steps to strengthen the Human Foods Program at the end of January and additional updates on the organizational structure, including how responsibilities of Mr. Yiannas’ position will be handled moving forward, by the end of February,” an FDA spokesperson said in a statement.





Source

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost
Health

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery.  Claude for Life Sciences is […]

Read More
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants 0 price for GLP-1s
Health

Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s

Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of their current list price. “In London, you’d buy a certain drug for $130 and even less than that … $88 […]

Read More
Trump announces efforts to expand access to IVF drugs
Health

Trump announces efforts to expand access to IVF drugs

U.S. President Donald Trump delivers remarks before signing an executive order on expanding access to IVF at his Mar-a-Lago resort on Feb. 18, 2025 in Palm Beach, Florida. Joe Raedle | Getty Images President Donald Trump on Thursday announced two new efforts to expand the availability of in vitro fertilization, the first concrete step from his […]

Read More